Stroke

A single-center study from India sheds light on the safety and efficacy of biosimilar tenecteplase relative to the reference agent for patients with acute ischemic stroke.

New data from a predefined secondary analysis of the STROKE-AF trial provides insight into the 3-year incidence of atrial fibrillation among patients with a history of ischemic stroke caused by atherosclerosis.

An analysis of data from the China Kadoorie Biobank study suggests cumulative exposure to estrogen was associated with stroke risk in postmenopausal women.

A study presented at the International Stroke Conference 2023 suggests the plasma metabolite gluconic acid could serve as a race-specific biomarker for identifying increased risk of hypertension and stroke in Black adults.

An analysis of registry data recorded in Denmark over a 4-decade period offers an overview of the risk of acute myocardial infarction and ischemic stroke incurred as a result of preeclampsia during pregnancy and how this risk changes over time.

Stroke symptoms that disappear in under an hour need emergency assessment to help prevent a full-blown stroke. A new scientific statement from the AHA provides guidance and a standardized approach to evaluating people with suspected TIA, particularly in rural areas.

An analysis of patient data from the REGARDS cohort suggests the increase in relative risk observed with traditional risk factors, such as hypertension and diabetes, on risk of stroke decreases as patients age, but investigators point out this does not diminish the importance of addressing these risk factors.

Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.

An analysis of data from a quality improvement initiative demonstrates the majority of patients continue their anticoagulant regimen beyond the guideline-directed 3 months following provoked VTE.

A new study encompassing data from more than 48,000,000 patients provides insight into the risk of major arterial and cerebrovascular diseases up to 49 weeks following initial COVID-19 diagnosis.

An analysis of data from the ARIC study provides insight into the impact of genetic risk scores on lifetime risk of stroke and how optimal cardiovascular health might influence this risk.

An analysis of data from more than 30k patients with DVT from the RIETE registry is providing clinicians with new insight into the difference in presentation and outcomes among patients with isolated distal DVT and proximal DVT.

An analysis of data from a single center in Switzerland from a 15-year period details the prevalence of undiagnosed major risk factors among patients admitted with acute ischemic stroke, suggesting 67.7% present with at least 1 undiagnosed risk factor.

Dr. Gregory Weiss provides perspective on a recent study detailing the risks of thrombosis observed with different COVID-19 vaccines among patients from a group of countries in Europe.

A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.

An analysis of national data from Sweden suggests men with prostate cancer were at a 48% greater risk of deep vein thrombosis and a 47% greater risk of pulmonary embolism compared to their counterparts without prostate cancer.

Published on May 17, the 2022 AHA/ASA guidelines for the management of intracerebral hemorrhage were created with the intent of replacing 2015 guidance with updated evidence-based recommendations.

A study from HRS 2022 suggests Black patients with AFib were 25% less likely to be on oral anticoagulants at hospital discharge compared to their White counterparts those discharged 18% less likely to receive DOACs than their White counterparts.

Data show 15-mg edoxaban dose was superior to placebo in preventing stroke or systemic embolism in all 3 age strata studied, with higher incidence of major bleeding.

After adjustment for age and sex, data show the reduction in mortality rates in the patients receiving dialysis was greater than the general population.

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Greater increases were observed among members of racial and ethnic minority groups, with the highest increase among non-Hispanic Black individuals.

Released on March 21, the practice advisory from the American Academy of Neurology advocates for a management approach focused on optimization of medical therapies and exercise over stenting for reducing risk of recurrent events and death in patients with symptomatic intracranial atherosclerotic arterial stenosis

An analysis of data from a prospective stroke registry suggests presence of hypertriglyceridemia was associated with a more than 2-fold increase in risk of MACE among patients with a history of acute stroke or TIA, even with adjustment for baseline LDL-C and statin use.

A new study suggests use of apixaban was associated with a lower rate of rehospitalization for VTE compared with warfarin in patients with VTE requiring extended anticoagulation.

Data show the absolute risk reductions of treatment with statins in terms of all-cause mortality, myocardial infarction, and stroke are modest compared with the relative risk reductions.

Data from Medicare beneficiaries provide insight into the risk of stroke associated with a diagnosis of COVID-19 among older adults, which results suggest peaks within the first 3 days of diagnosis.

A retrospective analysis of 10 years of stroke admissions suggests pediatric stroke patients with LVO who did not undergo thrombectomy were at 6 times greater risk of moderate to severe disability or death than those who underwent thrombectomy.

A retrospective chart review from ISC 2022 details the safety and efficacy of low-dose ticagrelor in clopidogrel-resistant neuroendovascular patients.

An international, retrospective analysis presented at ISC 2022 provides evidence suggesting use of DOACs as a treatment for cerebral venous thrombosis was associated with similar risk of recurrent clots and death as warfarin, but a 65% lower risk of major bleeding.